Current Trials and Studies

Part of the mission of The LAM Foundation is to fund promising research. Our researchers need your help in order to conduct their research. Please see the open protocols below to see if you meet any of the requirements and find out how you can participate.

Safety and Efficacy of Saracatnib in Subjects with Lymphangioleiomyomatosis 
SLAM-2 (New Phase 2a Open)

Dr. N. Tony Eissa at Baylor College of Medicine (main site for this multi-center study)
Women who are 18 years and older who have LAM are eligible to participate in this study. Subjects will be given 125 mg of saracaatnib for up to nine months. The entire duration of the study is 12 months. Seven visits will be required throughout the study.
The study is currently enrolling at the following locations (with more coming soon):

  • Stanford University - Stanford, CA
  • Baylor College of Medicine - Houston, TX
  • Loyola Medical Center – Chicago, IL
  • NHLBI - NIH – Bethesda, MD
  • University of Cincinnati – Cincinnati, OH
If you are interested in participating, please contact:

Caryn O. Pope, BSN, RRT, RCP
Clinical Research Coordinator
Baylor College of Medicine - Ben Taub General Hospital
Medicine: Pulmonary/Critical Care
1504 Taub Loop - 6PF 80-02
Houston, TX 77030
713-873-2471 (office)
713-796-9351 (fax)
CLICK HERE for more details about the study.

COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC

David Kwiatkowski, Brigham and Women's Hospital
We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
CLICK HERE for more details.

"BUILD" Biomarker Utility in LAM Diagnosis

Dr. Lisa Young at Vanderbilt University
*Females age 13 and older who have been diagnosed with LAM, either Sporadic LAM or TSC associated LAM
*Please note: Diagnosis of TSC is not required
CLICK HERE for more details


Dr. Francis X. McCormack at University of Cincinnati
Any woman diagnosed with LAM is eligible to participate in the MIDAS trial. It is important that all women with LAM at least contact the study coordinator to discuss the details of the study. NIH Continued funding of this study is dependent on Dr. McCormack and the other site's ability to enroll as many women with LAM as possible in the Multi center International Durability and Safety of Sirolimus in Lymphangioleiomyomatosis Trial (MIDAS Trial).
CLICK HERE for more details

Henske Lab

Dr. Elizabeth (Lisa) Henske’s laboratory has a new project to develop cellular models of LAM and angiomyolipomas to catalyze translational research. Please contact us if you are considering lung transplantation or any type of surgery. We are actively seeking tissue specimens from LAM, angiomyolipomas, lung transplantation, chylous fluid, uterine fibroids or tumors, or any other tissue or specimen from individuals with LAM or TSC. Please provide as much advance notice as possible so that the tissue can be properly collected. Please contact The LAM Foundation or 513-777-6889 if you are considering any type of surgery or biopsy. Thank you!

Safety Study of Simvastatin (SOS)

Dr. Vera Krymskaya
CLICK HERE for more details.

Study of the Disease Process of LAM

Dr. Joel Moss
CLICK HERE for more details.